anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a method for altering undesirable immune responses by identifying mutant polypeptides that exhibit less of an undesirable immune response while retaining one or more desired characteristics. Such polypeptides are safer and can be more efficacious when introduced into a human, other mammal, or other animal. Either the altered immune response or a surrogate for the immune response, referred to as a measurable immune characteristic, can be assessed in the method. Generally, the measurable immune characteristic can itself be an undesirable immune response, the measurable immune characteristic can be involved in an undesirable immune response, and/or an undesirable immune response can be mediated by the measurable immune characteristic. The disclosed method involves providing a collection of mutant polypeptides where the amino acid sequence of each mutant polypeptide differs in at least one position from a polypeptide of interest, identifying mutant polypeptides that exhibit less of the immune response than the polypeptide of interest, and identifying mutant polypeptides with less potential for eliciting an undesirable immune response that still retain the desired characteristic(s). The collection of mutant polypeptides can be provided by mutagenizing nucleic acid encoding a polypeptide of interest and expressing the mutagenized nucleic acid to produce mutant polypeptides. The method is especially useful for reducing immune responses involving both linear and/or conformational epitopes on a polypeptide of interest. This is possible because the recombinant polypeptides used as substrates for mutagenesis in the method are essentially full length, remaining structurally similar to the polypeptide of interest and displaying essentially the same conformational epitopes.
Spontaneous ruptured hepatocellular carcinoma (HCC) remains a life-threatening condition despite improvements in diagnostic methods and established treatment strategies. Although typical clinical presentations of spontaneous ruptured HCC facilitate easy diagnosis, this condition can present with unexpectedly varied symptoms, making diagnosis challenging. We describe an atypical clinical presentation of spontaneous ruptured HCC mimicking an inguinal hernia. A 66-year-old man presented to the emergency department with groin discomfort and swelling, suggesting an inguinal hernia. He had no history of an inguinal hernia or known liver cirrhosis. Physical examination revealed a palpable, tender left groin mass. Point-of-care ultrasonography showed bowel-like structures with an echo-free space in the left groin. Unenhanced computed tomography (CT) of the pelvis demonstrated mesenteric fat prolapse and hyperdense fluid in the left inguinal canal and scrotum. Considering the possibility of a strangulated hernia, emergency exploratory laparotomy was performed. Unexpectedly, blood retention in the hernia sac was found, with no intestinal involvement. Further exploration revealed a hematoma and tumor on the liver surface. Finally, he was diagnosed with spontaneous ruptured HCC and underwent successful emergency hepatic resection. Spontaneous ruptured HCC can potentially mimic other abdominal conditions such as an inguinal hernia, even in cases of undiagnosed liver cirrhosis. Although unenhanced CT can reveal bloody ascites suggesting hemoperitoneum, the underlying cause should be carefully considered. Emergency physicians should recognize various clinical presentations of spontaneous ruptured HCC to ensure prompt diagnosis and treatment of this potentially fatal complication.
Hemiparesis of the upper limb is one of the most serious and most common impairments resulting from stroke. Approximately 75% of the over 750,000 strokes that occur annually in the United States cause some degree of upper extremity paralysis. Approximately 65% of stroke survivors still cannot use their affected hand to assist with activities of daily living 6 months after their stroke. The impact of upper extremity impairments on disability and health is great, yet there are relatively few rehabilitation interventions designed to restore function to the impaired upper limb. Therefore, our long-term objective is to develop upper extremity rehabilitation therapies that are effective at restoring arm and hand function, that are applicable across a wide range of impairment severity, and that are readily implemented in the present healthcare environment.

The purpose of this study is to estimate the efficacy of Contralataterally Controlled Functional Electrical Stimulation (CCFES) in reducing upper extremity impairment and activity limitation in chronic upper extremity hemiplegia. CCFES is a rehabilitation intervention in which neuromuscular electrical stimulation (NMES) is applied to the finger and thumb extensor muscles of the paretic upper limb to open the hand. The stroke survivor controls the stimulation intensity, and consequent degree of hand opening, by modulating the degree of opening of the contralateral unimpaired hand, which is detected by an instrumented glove. Thus, volitional opening of the unaffected hand produces stimulated opening of the affected hand. The stimulation paradigm is used to assist the stroke survivor in practicing functional tasks with their affected hand. We will conduct a randomized controlled trial in which chronic stroke survivors (\>6 months post-stroke) will be randomly assigned to receive 12 weeks of CCFES or cyclic NMES, an intervention that provides electrical stimulation of the hand extensors, but with preprogrammed timing and intensity. Randomization will be stratified on two levels of baseline hand impairment defined by the degree of voluntary finger extension present. Assessments of upper extremity impairment and activity limitation will be made every 3 weeks during the treatment period and every 2 months during a 6-month follow-up period.

This study is the first randomized controlled trial of CCFES in chronic upper extremity hemiplegia. Ultimately, the information learned in this study will serve to accelerate the development of treatments for reducing post-stroke disability.
Much of the image processing that is applied to medical images is a form of “inverse problem”. This is a class of mathematical problems in which a “forward” model by which a signal is converted into dataset is known, to at least some degree, but where the aim is to reconstruct the signal given the resulting dataset. Thus, an inverse problem is essentially seeking to discover x given knowledge of A(x)+noise by finding an appropriate reconstruction operator A †  such that A †  (A(x)+noise)≈x, thereby enabling us to obtain x (or a close approximation) given knowledge of an output dataset consisting of A(x)+noise. Generally, several such processes (or their equivalents) are applied to the image dataset. If the first process (for example, noise reduction) is expressed via a first reconstruction operator A 1   †  characterised by a parameter set Θ 1  and the second process (for example, segmentation) is expressed via a second reconstruction operator A 2   †  characterised by a parameter set Θ 2 , then the result of the two steps applied consecutively is A 2   †  (A 1   † (y)). This can be expressed as an overall reconstruction operator P + , characterised by a parameter set Φ. If we then allow a machine learning process to optimise P + , then the steps previously carried out separately can be combined into a single optimisation. This yields advantages in terms of computational load and in the accuracy of the end result.
The invention relates to a Chinese medicinal preparation for treating a cardiovascular disease. The Chinese medicinal preparation is prepared from the following bulk pharmaceuticals by weight: 20g of Chinese angelica root-tip, 20g of red-rooted salvia root, 15g of common selfheal fruit-spike, 10g of saffron crocus, 15g of bitter orange, 15g of earthworm, 10g of peach kernel, 20g of dwarf lilyturf root, 20g of twotooth achyranthes root, 10g of weeping forsythia, 10g of motherwort herb, 15g of tuber fleeceflower root, 20g of fructus crataegi and 6g of liquoric root. A preparation method of the Chinese medicinal preparation comprises the following steps of: adding 1,500ml of water into the Chinese medicines; boiling with intense fire; decocting with slow fire for 30 minutes; and filtering residues out to obtain a decoction. During treatment, one dose is taken every day, and a treatment course lasts for 10 days. These medicines can be combined for clearing heat, relieving fever, replenishing qi, enriching the blood, promoting blood circulation to restore menstrual flow, eliminating stagnation and removing blood stasis, and good prevention and treatment effects on the cardiovascular disease are achieved. The Chinese medicinal preparation has quick response and small side effects.
Hemiplegic shoulder pain treatment methods are, analgesics, local steroid injection, physical therapy modalities and exercise. There are publications about the use of TENS and interferential currents (IFC) in the treatment of hemiplegia related shoulder pain and their effectiveness. However when we look at the literature, we did not find a study that evaluated the efficacy of TENS and IFC in hemiplegic shoulder pain. For this reason, in this study, we aimed to determine the effects of these analgesic treatment modalities on the patient's pain, functional status and shoulder range of motion (ROM) in these patients. 60 stroke patients with shoulder pain randomized to four treatment groups. 15 patients in Group 1 were given TENS treatment to the shoulder area for 25 minutes by conventional method ( 20 sessions, 5 times a week), then, a classical stroke rehabilitation program was applied under the guidance of a physiotherapist.. 15 patients in Group 2 were given shamTENS treatment to the shoulder area for 25 minutes ( 20 sessions, 5 times a week), then, a classical stroke rehabilitation program was applied under the guidance of a physiotherapist.15 patients in Group 3 were given 100 Hz IFC treatment to the shoulder area for 25 minutes ( 20 sessions, 5 times a week), then, a classical stroke rehabilitation program was applied under the guidance of a physiotherapist. 15 patients in Group 4 were given shamIFC treatment to the shoulder area for 25 minutes ( 20 sessions, 5 times a week), then, a classical stroke rehabilitation program was applied under the guidance of a physiotherapist.
The current study aims to assess the long-term analgesic efficacy of interoceptive tactile stimulation in patients suffering from chronic moderate-to-severe osteoarthritis (OA) pain. The study will be a randomized, double-blind, sham-controlled crossover trial involving 60 OA patients with moderate-to-severe chronic pain. Patients will be randomly assigned to the treatment or control group and received interoceptive (affective touch) or control stimulation two days a week for 12 weeks. Patient will then undergo to a 4-week washout period, after that they will be assigned to the crossover treatment for another 12 weeks. The study will measure changes in pain and physical function, heart rate variability, as well as inflammatory and anti-inflammatory cytokines and medication intake, assessed at baseline, and at the end of each crossover phase. Follow-up measures will be assessed 4 weeks after the end of each crossover phase. Intermediate outcomes for pain and physical function, heart rate variability and medication intake will also be assessed after 4 and 8 weeks.
A pharmaceutical dosage form for the release of at least one pharmaceutically active ingredient is claimed. The pharmaceutical dosage form includes a polymer matrix, polymer-lipid nanoparticles incorporated within the matrix and the pharmaceutically active ingredient(s). The polymer matrix is formed from at least two crosslinked cationic and anionic polymers, such as Eudragit TM E100 and sodium carboxymethlycellulose. It can also include a neutral polymer, such as one derived from locust bean. The polymer-lipid nanoparticles are formed from at least one polymer, such as Eudragit TM E100 and/or chitosan, and at least one phospholipid, such as lecithin. The polymer(s) and phospholipid are crosslinking with a chelating agent, such as sodium tripolyphosphate. The active ingredient or ingredients can be any pharmaceutically active compound(s), and in particular poorly absorbed compounds such as levodopa for the treatment of Parkinson's disease.
FIELD: veterinary science. SUBSTANCE: vaccine preparation against infections in poultry, for example, egg yield decrease syndrome virus, Newcastle disease of infectious bronchitis in chickens and infectious bursitis where antigens are placed in liposomal vesicle which, in turn, is places in an envelope made of a mixture of sugars and water-soluble polymeric materials in the following ratio of components, wt. -%: sugars, 8-15; water-soluble polymer, 0.5-3; antigen in liposomal vesicle, the balance. Preparation has sucrose, lactose and/or sorbitol as sugars; gelatin, polyglucin or polyvinylpyrrolidone as a water-soluble material. Method of poultry vaccination involves administration of liposomal vaccine in birds by oral method in the dose 10 ml per a head. One man is able to vaccinate 25 000-30 000 heads of birds for 2 h while for intramuscular injections of this herd 6 men must work for 2 days. EFFECT: enhanced effectiveness of vaccine, improved method of vaccination. 4 cl, 5 tbl, 2 ex
PURPOSE: A treating agent for peptic ulcer obtained by extracting Ulmus parvifolia Jacq. with an organic solvent or aqueous solution is provided, which has excellent anti-peptic ulcer activity with low toxicity. CONSTITUTION: The titled agent for treating peptic ulcer contains an Ulmus parvifolia Jacq. extract and pharmaceutically acceptable carrier. The extract is administered in an amount of 1 to 500kg per 1kg adult one time. For an example, 10L organic solvent is added to 1kg Ulmus parvifolia Jacq., refluxed at 40 to 80deg.C for 3 hr., filtered, concentrated and freeze-dried to give 150g extract.
The invention relates to a cancer recognition factor (SCM-factor), its use and method of preparation. The SCM-factor of the invention is characterized as a low molecular weight peptide which is distinguished by its ability to produce a ten percent to fifty percent decrease in the intracellular fluorescein fluorescence polarization value of SCM-responding lymphocytes derived from the blood samples of donors afflicted with cancer. The SCM-factor is also characterized by its ability, after prolonged contact with SCM-responding lymphocytes, to modify the SCM-response of lymphocytes from donors not afflicted with cancer so that such lymphocytes respond in the SCM-test in all respects like lymphocytes from donors afflicted with cancer. The SCM-factor is isolated from a body fluid such as blood or urine by first subjecting the body fluid to ultrafiltration through a filter with a 1000 Dalton molecular weight cutoff. Following ultrafiltration the filtrate may be lyophilized or stored at 4°C or immediately purified by elution with distilled water through a chromatographic column and collecting elution fractions of between 0.3 and 0.5 Ve/Vt. The collected fractions may be further purified by elution with aqueous ammonium bicarbonate through a chromatographic column saving the elution fractions of between 0.4 and 0.6 Ve/Vt. If desired the samples may be even further purified by passage through a column packed with anion exchange material followed by reverse phase high pressure liquid chromatography purification. The SCM-factor is used for general screening of blood samples for the presence of malignancy in the donor body.
Dose Level -1 represents a dose that may be evaluated if dose level 1 is poorly tolerated. No dose de-escalation below this level is planned for this study. If the dose level -1 is poorly tolerated, the study will be terminated.
Efficacy in the pediatric population has not been demonstrated.

The pharmacokinetics of tolterodine extended release capsules have been evaluated in pediatric patients ranging in age from 11–15 years. The dose-plasma concentration relationship was linear over the range of doses assessed. Parent/metabolite ratios differed according to CYP2D6 metabolizer status [see CLINICAL PHARMACOLOGY (12.3)]. CYP2D6 extensive metabolizers had low serum concentrations of tolterodine and high concentrations of the active metabolite 5-HMT, while poor metabolizers had high concentrations of tolterodine and negligible active metabolite concentrations.

A total of 710 pediatric patients (486 on DETROL LA, 224 on placebo) aged 5–10 with urinary frequency and urge incontinence were studied in two randomized, placebo-controlled, double-blind, 12-week studies. The percentage of patients with urinary tract infections was higher in patients treated with DETROL LA (6.6%) compared to patients who received placebo (4.5%). Aggressive, abnormal, and hyperactive behavior and attention disorders occurred in 2.9% of children treated with DETROL LA compared to 0.9% of children treated with placebo.
The fracture and malunion patients need osteosynthesis or osteotomy will be recruited. Image fusion group utilizes 3D preoperative planning and image fusion system. Control group utilizes only 3D preoperative planning. The age, sex, and fracture types will be matched between groups. In both groups, 3D preoperative planning will be performed in order to determine reduction, placement and choices of implants. In the image fusion group, the outline of planned image will be displayed on the monitor overlapping with fluoroscopy image during surgery. Reductions, implant choices/positions, and clinical outcomes will be evaluated.
There are significant safety and image quality issues associated with transferring neonates from the Neonatal Intensive Care Unit (NICU) to the main Radiology Department for imaging in an adult-sized magnetic resonance imaging (MRI) scanner. For these reasons, the smallest and/or sickest neonates are typically precluded from receiving an MRI exam. The goal of our research effort is to bring high-performance MRI into the NICU so that all neonates can benefit from the same quality of diagnostic imaging as adults. To accomplish this, we have converted a commercial small-bore 1.5 Tesla (T) MRI scanner designed for orthopedic use into a neonatal MRI system optimized for whole body imaging of neonates (NICU MRI). To expand the imaging capabilities of the NICU MRI system, the measurement control electronics and operating system software of the FDA cleared OPTIMA platform have been augmented with state of the art HDX electronics and software currently used on a conventional commercially available adult sized whole body MRI scanner. The clinical safety of the integrated HDX/OPTIMA NICU MRI system and its ability to produce diagnostic image quality has been shown in 15 pilot patients (CCHMC Protocol 2011-2045). Further we have scanned almost 600 patients under a prior protocol (CCHMC Protocol 2011-2850) without an adverse event.

The present protocol seeks to allow continued performance of clinical MRI exams on the NICU magnet with improved administrative processes and procedures. NICU patients for whom an MRI exam is medically indicated will be recruited for the present study. Images will be obtained using both the FDA cleared OPTIMA NICU MRI platform and the integrated HDX/OPTIMA NICU MRI platform with the additional HDX images augmenting the OPTIMA images and contributing to diagnosis and guidance of subsequent clinical management. The specific MR imaging methods/procedures utilized will be determined by the type of exam to be performed and the medical indication. All of the MR images obtained will be reviewed by a board certified pediatric radiologist as part of clinical care and a clinical report will be generated and included in the infant's medical record.
BACKGROUND: Around 10% of people infected by SARS-COV-2 report symptoms that persist longer than 3 months. Little has been reported about sex differences in symptoms and clustering over time of non-hospitalised patients in primary care settings.
METHODS: This is a descriptive study of a cohort of mainly non-hospitalized patients with a persistence of symptoms longer than 3 months from the clinical onset in co-creation with the Long Covid Catalan affected group using an online survey. Recruitment was from March 2020 to June 2021. Exclusion criteria were being admitted to an ICU, < 18 years of age and not living in Catalonia. We focused on 117 symptoms gathered in 18 groups and performed cluster analysis over the first 21 days of infection, at 22-60 days, and ≥ 3 months.
RESULTS: We analysed responses of 905 participants (80.3% women). Median time between symptom onset and the questionnaire response date was 8.7 months. General symptoms (as fatigue) were the most prevalent with no differences by sex, age, or wave although its frequency decreased over time (from 91.8 to 78.3%). Dermatological (52.1% in women, 28.5% in men), olfactory (34.9% women, 20.9% men) and neurocognitive symptoms (70.1% women, 55.8% men) showed the greatest differences by sex. Cluster analysis showed five clusters with a predominance of Taste & smell (24.9%) and Multisystemic clusters (26.5%) at baseline and _Multisystemic (34.59%) and Heterogeneous (24.0%) at ≥3 months. The Multisystemic cluster was more prevalent in men. The Menstrual cluster was the most stable over time, while most transitions occurred from the Heterogeneous cluster to the Multisystemic cluster and from Taste & smell to Heterogeneous.
CONCLUSIONS: General symptoms were the most prevalent in both sexes at three-time cut-off points. Major sex differences were observed in dermatological, olfactory and neurocognitive symptoms. The increase of the Heterogeneous cluster might suggest an adaptation to symptoms or a non-specific evolution of the condition which can hinder its detection at medical appointments. A carefully symptom collection and patients' participation in research may generate useful knowledge about Long Covid presentation in primary care settings.
BACKGROUND: The incidence of cervical intraepithelial neoplasia is increasing in Japan. Although human papillomavirus (HPV) vaccination and cancer screening are crucial in preventing cancer-related mortality, the cervical cancer screening rate in Japan was only approximately 43.6% in 2022. This study aimed to conduct an epidemiological analysis of cervical cancer by collecting data from individual patients.
METHODS: A questionnaire survey was administered to patients who visited our hospital between January 2017 and July 2023 owing to abnormal cervical cytological findings or a cancer diagnosis. Patients answered questions regarding their history of cervical cancer screening as well as their knowledge of HPV and cervical cancer.
RESULTS: During the study period, 471 patients participated in the survey, with 35 declining to participate. Patients with Stage 1b1-4b primarily sought medical attention due to self-reported symptoms (P < 0.001); however, they were less likely to have undergone cervical cancer screening (P < 0.001). Additionally, older patients were less likely to be aware of the association of HPV with cervical and other cancers. Notably, 28 of the 129 patients with stage 1b1-4b cancer underwent cervical cancer screening within 2 years. The tumor location within the endocervical canal emerged as a significant factor contributing to the difficulty for an accurate diagnosis of precancerous or cervical cancer during cervical screening. Furthermore, non- squamous cell carcinoma (SCC) histology was another possible factor.
CONCLUSIONS: Our findings suggest the need to widely disseminate information regarding the significance of cancer screening to increase cancer screening rates. Moreover, establishing strategies for improving the accuracy of detecting lesions during screening for non-SCC and endocervical canal tumors is crucial.